Results
1 -
7 of
7Ma Xiao-Dong, Qiu Ni, Yang Bo, He Qiao-Jun, Hu Yong-Zhou.
Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation, Med. Chem. Commun., 2016 C. Fraser, N. O. Carragher, A. Unciti-Broceta.
3 TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies, Cancer Chemotherapy and Pharmacology The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer, Breast Cancer Research and Treatment Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo, Tumor Biology Merkel Cell Carcinoma Therapeutic Update, Current Treatment Options in Oncology C. Borsari, E. Keles, A. Treyer, M. De Pascale, P. Hebeisen, M. Hamburger, M. P. Wymann.
4